90,000 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Purchased by General American Investors Co. Inc.

General American Investors Co. Inc. purchased a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 90,000 shares of the company's stock, valued at approximately $2,851,000. General American Investors Co. Inc. owned approximately 0.12% of IDEAYA Biosciences as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of IDYA. Allworth Financial LP lifted its holdings in shares of IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company's stock valued at $29,000 after acquiring an additional 800 shares during the last quarter. Covestor Ltd lifted its stake in shares of IDEAYA Biosciences by 9,225.0% in the 1st quarter. Covestor Ltd now owns 1,119 shares of the company's stock valued at $49,000 after purchasing an additional 1,107 shares during the last quarter. Quest Partners LLC purchased a new position in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $41,000. Comerica Bank increased its position in shares of IDEAYA Biosciences by 723.5% during the 1st quarter. Comerica Bank now owns 1,507 shares of the company's stock valued at $66,000 after purchasing an additional 1,324 shares during the last quarter. Finally, US Bancorp DE raised its holdings in IDEAYA Biosciences by 67.2% during the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company's stock valued at $54,000 after buying an additional 689 shares during the period. Institutional investors own 98.29% of the company's stock.

Analysts Set New Price Targets

IDYA has been the topic of a number of analyst reports. Leerink Partnrs cut shares of IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday. Citigroup reduced their price objective on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a "buy" rating on the stock in a research report on Tuesday, August 27th. Stifel Nicolaus raised their price objective on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a "buy" rating in a research note on Tuesday, September 10th. UBS Group started coverage on IDEAYA Biosciences in a research note on Thursday, October 24th. They set a "buy" rating and a $50.00 target price on the stock. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $53.08.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA traded down $0.42 during trading hours on Thursday, reaching $29.99. The company had a trading volume of 505,714 shares, compared to its average volume of 851,221. The firm has a market cap of $2.53 billion, a PE ratio of -12.87 and a beta of 0.86. IDEAYA Biosciences, Inc. has a 1-year low of $27.52 and a 1-year high of $47.74. The business's 50 day moving average price is $32.57 and its 200-day moving average price is $36.79.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.03. During the same quarter in the previous year, the firm posted ($0.46) earnings per share. On average, analysts expect that IDEAYA Biosciences, Inc. will post -2.51 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.